Episurf Medical acquires properties in Borås - Episurf Medical

Episurf Medical acquires properties in Borås

The acquisition in brief

Two properties in Räveskalla, Borås (Räveskalla 1:435 and Räveskalla 1:506), with a total lettable area of 1,735 sqm.
Agreed property value of SEK 12 mn after deduction of deferred tax.
Fully let with a net operating income (NOI) of approximately SEK 1.0 mn per year, corresponding to a NOI yield of 8.4 per cent.
Stable cash flows with a weighted average unexpired lease term (WAULT) of 6.5 years.
Preliminary completion on 1 July 2026.

Financing

The acquisition is intended to be financed through a combination of consideration shares in the form of newly issued class B shares to be issued in connection with or shortly after completion, a convertible loan and a loan from a bank or credit institution. The newly issued class B shares are intended to be issued at a subscription price of SEK 0.10 per class B share and increasing conversion prices of SEK 0.11, SEK 0.12 and SEK 0.13 based on the time of conversion. The terms of the share issue in kind, including the number of shares and dilution, will be disclosed in connection with the issue resolution.

Background and rationale

The acquisition represents a further step in the Company’s strategy of building a broad and cash-flow-generating property platform with a focus on properties offering a sound yield. The properties are fully let to three tenants active within industry, logistics and storage, providing stable and predictable cash flows.

For further information, please contact:

Jens Andersson, CEO, Episurf Medical

Tel: +46 (0) 768 55 67 02

Email: jens.andersson@episurf.com

About Episurf Medical AB

Episurf Medical is a real estate company with exposure to a diversified portfolio of property assets. The Company’s objective is to create value growth through the acquisition and management of Nordic properties. The Company also has a medical technology operation based on the individualised Episealer® implant and associated surgical instruments, used to treat cartilage injuries in joints. Episurf Medical’s head office is located in Stockholm, Sweden.

THIS PRESS RELEASE HAS BEEN PUBLISHED IN SWEDISH AND ENGLISH. IN THE EVENT OF ANY DISCREPANCY BETWEEN THE LANGUAGE VERSIONS, THE SWEDISH VERSION SHALL PREVAIL.

CisionBlockPro\Cision\FeedItem Object
(
    [HtmlCompanyInformation:protected] => 
    [HtmlContact:protected] => 
    [HtmlTitle:protected] => <h1 style="line-height:120%"><span style="font-family:arial,helvetica,sans-serif">Episurf Medical acquires properties in Bor&aring;s</span></h1>
    [HtmlHeader:protected] => 
    [HtmlIntro:protected] => <p><span style="font-size:11pt"><span style="font-family:arial,helvetica,sans-serif">Episurf Medical AB (publ) (Nasdaq: EPIS B) has entered into an agreement to acquire all shares in HanssonGruppen Räveskalla AB. The acquisition comprises two properties in Räveskalla, Borås, with a total lettable area of 1,735 sqm, and strengthens the Company’s property portfolio with fully let light-industrial premises generating stable cash flows.</span></span></p>
    [Body:protected] => The acquisition in brief
  · Two properties in Räveskalla, Borås (Räveskalla 1:435 and Räveskalla 1:506), with a total lettable area of 1,735 sqm.
  · Agreed property value of SEK 12 mn after deduction of deferred tax.
  · Fully let with a net operating income (NOI) of approximately SEK 1.0 mn per year, corresponding to a NOI yield of 8.4 per cent.
  · Stable cash flows with a weighted average unexpired lease term (WAULT) of 6.5 years.
  · Preliminary completion on 1 July 2026.
Financing
The acquisition is intended to be financed through a combination of consideration shares in the form of newly issued class B shares to be issued in connection with or shortly after completion, a convertible loan and a loan from a bank or credit institution. The newly issued class B shares are intended to be issued at a subscription price of SEK 0.10 per class B share and increasing conversion prices of SEK 0.11, SEK 0.12 and SEK 0.13 based on the time of conversion. The terms of the share issue in kind, including the number of shares and dilution, will be disclosed in connection with the issue resolution.
Background and rationale
The acquisition represents a further step in the Company’s strategy of building a broad and cash-flow-generating property platform with a focus on properties offering a sound yield. The properties are fully let to three tenants active within industry, logistics and storage, providing stable and predictable cash flows.
For further information, please contact:
Jens Andersson, CEO, Episurf Medical
Tel: +46 (0) 768 55 67 02
Email: jens.andersson@episurf.com
About Episurf Medical AB
Episurf Medical is a real estate company with exposure to a diversified portfolio of property assets. The Company’s objective is to create value growth through the acquisition and management of Nordic properties. The Company also has a medical technology operation based on the individualised Episealer® implant and associated surgical instruments, used to treat cartilage injuries in joints. Episurf Medical’s head office is located in Stockholm, Sweden.
THIS PRESS RELEASE HAS BEEN PUBLISHED IN SWEDISH AND ENGLISH. IN THE EVENT OF ANY DISCREPANCY BETWEEN THE LANGUAGE VERSIONS, THE SWEDISH VERSION SHALL PREVAIL.
    [HtmlBody:protected] => <h2 style="margin-bottom:8px; margin-top:13px"><span><span style="font-size:12pt"><span style="font-family:arial,helvetica,sans-serif">The acquisition in brief</span></span></span></h2>
<ul>
	<li style="margin-bottom: 3px; margin-left: 8px; font-size: 11pt; font-family:arial,helvetica,sans-serif;"><span><span style="font-size:11pt"><span style="font-family:arial,helvetica,sans-serif">Two properties in Räveskalla, Borås (Räveskalla 1:435 and Räveskalla 1:506), with a total lettable area of 1,735 sqm.</span></span></span></li>
	<li style="margin-bottom: 3px; margin-left: 8px; font-size: 11pt; font-family:arial,helvetica,sans-serif;"><span><span style="font-size:11pt"><span style="font-family:arial,helvetica,sans-serif">Agreed property value of SEK 12 mn after deduction of deferred tax.</span></span></span></li>
	<li style="margin-bottom: 3px; margin-left: 8px; font-size: 11pt; font-family:arial,helvetica,sans-serif;"><span><span style="font-size:11pt"><span style="font-family:arial,helvetica,sans-serif">Fully let with a net operating income (NOI) of approximately SEK 1.0 mn per year, corresponding to a NOI yield of 8.4 per cent.</span></span></span></li>
	<li style="margin-bottom: 3px; margin-left: 8px; font-size: 11pt; font-family:arial,helvetica,sans-serif;"><span><span style="font-size:11pt"><span style="font-family:arial,helvetica,sans-serif">Stable cash flows with a weighted average unexpired lease term (WAULT) of 6.5 years.</span></span></span></li>
	<li style="margin-bottom: 11px; margin-left: 8px; font-size: 11pt; font-family:arial,helvetica,sans-serif;"><span><span style="font-size:11pt"><span style="font-family:arial,helvetica,sans-serif">Preliminary completion on 1 July 2026.</span></span></span></li>
</ul>
<h2 style="margin-bottom:8px; margin-top:13px"><span><span style="font-size:12pt"><span style="font-family:arial,helvetica,sans-serif">Financing</span></span></span></h2>
<p style="margin-bottom:11px;margin-top:12px"><span><span style="font-size:11pt"><span style="font-family:arial,helvetica,sans-serif">The acquisition is intended to be financed through a combination of consideration shares in the form of newly issued class B shares to be issued in connection with or shortly after completion, a convertible loan and a loan from a bank or credit institution. The newly issued class B shares are intended to be issued at a subscription price of SEK 0.10 per class B share and increasing conversion prices of SEK 0.11, SEK 0.12 and SEK 0.13 based on the time of conversion. The terms of the share issue in kind, including the number of shares and dilution, will be disclosed in connection with the issue resolution.</span></span></span></p>
<h2 style="margin-bottom:8px; margin-top:13px"><span><span style="font-size:12pt"><span style="font-family:arial,helvetica,sans-serif">Background and rationale</span></span></span></h2>
<p style="margin-bottom:11px"><span><span style="font-size:11pt"><span style="font-family:arial,helvetica,sans-serif">The acquisition represents a further step in the Company’s strategy of building a broad and cash-flow-generating property platform with a focus on properties offering a sound yield. The properties are fully let to three tenants active within industry, logistics and storage, providing stable and predictable cash flows.</span></span></span></p>
<h2 style="margin-bottom:8px; margin-top:13px"><span><span style="font-size:12pt"><span style="font-family:arial,helvetica,sans-serif">For further information, please contact:</span></span></span></h2>
<p style="margin-bottom:11px"><span><span style="font-size:11pt"><span style="font-family:arial,helvetica,sans-serif">Jens Andersson, CEO, Episurf Medical</span></span></span></p>
<p style="margin-bottom:11px"><span><span style="font-size:11pt"><span style="font-family:arial,helvetica,sans-serif">Tel: +46 (0) 768 55 67 02</span></span></span></p>
<p style="margin-bottom:11px"><span><span style="font-size:11pt"><span style="font-family:arial,helvetica,sans-serif">Email: jens.andersson@episurf.com</span></span></span></p>
<h2 style="margin-bottom:8px; margin-top:13px"><span><span style="font-size:12pt"><span style="font-family:arial,helvetica,sans-serif">About Episurf Medical AB</span></span></span></h2>
<p style="margin-bottom:11px"><span><span style="font-size:11pt"><span style="font-family:arial,helvetica,sans-serif"><em>Episurf Medical is a real estate company with exposure to a diversified portfolio of property assets. The Company’s objective is to create value growth through the acquisition and management of Nordic properties. The Company also has a medical technology operation based on the individualised Episealer® implant and associated surgical instruments, used to treat cartilage injuries in joints. Episurf Medical’s head office is located in Stockholm, Sweden.</em></span></span></span></p>
<p style="margin-bottom:11px; margin-top:16px"><span><span style="font-size:11pt"><span style="font-family:arial,helvetica,sans-serif"><strong><em>THIS PRESS RELEASE HAS BEEN PUBLISHED IN SWEDISH AND ENGLISH. IN THE EVENT OF ANY DISCREPANCY BETWEEN THE LANGUAGE VERSIONS, THE SWEDISH VERSION SHALL PREVAIL.</em></strong></span></span></span></p>
    [ServiceCategories:protected] => Array
        (
            [0] => CisionBlockPro\Cision\ServiceCategory Object
                (
                    [ServiceName:protected] => NASDAQ nonreg
                    [Name:protected] => OMX CategoryCode
                    [Value:protected] => 55
                )
        )
    [LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
    [CompanyInformation:protected] => 
    [Contact:protected] => 
    [Header:protected] => 
    [Keywords:protected] => Array
        (
        )
    [QuickFacts:protected] => Array
        (
        )
    [Categories:protected] => Array
        (
        )
    [Videos:protected] => Array
        (
        )
    [Files:protected] => Array
        (
            [0] => CisionBlockPro\Cision\File Object
                (
                    [IsMain:protected] => 1
                    [MediaType:protected] => File
                    [Url:protected] => https://mb.cision.com/Main/14691/4353187/4114447.pdf
                    [FileName:protected] => wkr0006.pdf
                    [Title:protected] => Release
                    [Description:protected] => Release
                    [CreateDate:protected] => 2026-05-26T10:00:20.4Z
                    [Keywords:protected] => Array
                        (
                        )
                    [Extension:protected] => pdf
                )
        )
    [Quotes:protected] => Array
        (
        )
    [ExternalLinks:protected] => Array
        (
        )
    [EmbeddedItems:protected] => Array
        (
        )
    [Id:protected] => 5370393
    [EncryptedId:protected] => 76834D8CD3704932
    [IsRegulatory:protected] => 
    [PublishDate:protected] => 2026-05-26T10:00:07Z
    [LastChangeDate:protected] => 2026-05-26T10:00:20.383Z
    [Title:protected] => Episurf Medical acquires properties in Borås
    [Intro:protected] => Episurf Medical AB (publ) (Nasdaq: EPIS B) has entered into an agreement to acquire all shares in HanssonGruppen Räveskalla AB. The acquisition comprises two properties in Räveskalla, Borås, with a total lettable area of 1,735 sqm, and strengthens the Company’s property portfolio with fully let light-industrial premises generating stable cash flows.
    [IptcCode:protected] => 04004003
    [InformationType:protected] => PRM
    [LanguageCode:protected] => en
    [CountryCode:protected] => se
    [CanonicalUrl:protected] => 
    [CisionWireUrl:protected] => https://news.cision.com/episurf/r/episurf-medical-acquires-properties-in-boras,c4353187
    [LanguageVersions:protected] => Array
        (
            [0] => CisionBlockPro\Cision\LanguageVersion Object
                (
                    [Code:protected] => sv
                    [ReleaseId:protected] => 5370392
                )
        )
    [Images:protected] => Array
        (
        )
    [Tickers:protected] => Array
        (
            [0] => stdClass Object
                (
                    [Symbol] => EPIS B
                    [ISIN] => SE0003491562
                    [PrimaryListing] => 1
                    [IsShare] => 1
                    [MarketPlaceSymbol] => STO
                    [MarketPlaceName] => Stockholmsbörsen
                    [MarketPlaceBloombergCode] => SS
                    [MarketPlaceMarketWireCode] => OMX
                    [MarketPlaceIsRegulated] => 1
                    [MarketPlaceCountryCode] => SE
                )
        )
)